ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

IDYA IDEAYA Biosciences Inc

41.00
0.68 (1.69%)
21 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
IDEAYA Biosciences Inc NASDAQ:IDYA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.68 1.69% 41.00 16.32 44.89 42.20 39.90 40.28 1,505,818 23:25:00

IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event

01/05/2024 11:00am

PR Newswire (US)


IDEAYA Biosciences (NASDAQ:IDYA)
Historical Stock Chart


From Apr 2024 to May 2024

Click Here for more IDEAYA Biosciences Charts.

SOUTH SAN FRANCISCO, Calif., May 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.

(PRNewsfoto/IDEAYA Biosciences, Inc.)

RBC Capital Markets Global Healthcare Conference
Tuesday, May 14th, 2024 at 3:05 PM ET

  • Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Gregory Renza, Director and Senior Biotechnology Research Analyst

A live audio webcast of the conference event, as permitted by the conference host, will be available at the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host.  A replay of available webcasts will be accessible for 30 days following the live event.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.  IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. 

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Annual Report on Form 10-K filed on February 20, 2024 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-may-2024-investor-relations-event-302130345.html

SOURCE IDEAYA Biosciences, Inc.

Copyright 2024 PR Newswire

1 Year IDEAYA Biosciences Chart

1 Year IDEAYA Biosciences Chart

1 Month IDEAYA Biosciences Chart

1 Month IDEAYA Biosciences Chart